Genix Pharmaceuticals Stock Debt To Equity
| GENPF Stock | USD 0.02 0.00 0.00% |
Fundamental analysis of Genix Pharmaceuticals allows traders to better anticipate movements in Genix Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Genix |
Genix Pharmaceuticals Company Debt To Equity Analysis
Genix Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Genix Pharmaceuticals Debt To Equity | 0.06 % |
Most of Genix Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genix Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Genix Pharmaceuticals has a Debt To Equity of 0.055%. This is 99.9% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The debt to equity for all United States stocks is 99.89% higher than that of the company.
Genix Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genix Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Genix Pharmaceuticals by comparing valuation metrics of similar companies.Genix Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Genix Fundamentals
| Return On Equity | -0.31 | |||
| Return On Asset | -0.16 | |||
| Current Valuation | 3.14 M | |||
| Shares Outstanding | 59.22 M | |||
| Shares Owned By Insiders | 44.54 % | |||
| Price To Book | 1.55 X | |||
| Price To Sales | 5,785 X | |||
| Gross Profit | (4.71 K) | |||
| EBITDA | (1.11 M) | |||
| Net Income | (1.65 M) | |||
| Cash And Equivalents | 55.34 K | |||
| Total Debt | 189.54 K | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 0.14 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (428.31 K) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | -0.77 | |||
| Market Capitalization | 3.91 M | |||
| Total Asset | 4.77 M | |||
| Z Score | 12.0 | |||
| Net Asset | 4.77 M |
About Genix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genix Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genix Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Genix Pink Sheet
Genix Pharmaceuticals financial ratios help investors to determine whether Genix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genix with respect to the benefits of owning Genix Pharmaceuticals security.